# Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Mu

Source: https://onco.cc/trials/nct06538896/  
OnCo record `nct06538896` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tislelizumab and nab-paclitaxel in triple-negative breast cancer, run by Zhejiang Cancer Hospital, now recruiting.

## Summary

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study is a phase 2, interventional study registered as NCT06538896 by Zhejiang Cancer Hospital, with a registry enrolment figure of 20 participants, started 2024-08-20 and due to reach its primary completion in 2026-12. Interventions recorded: Tislelizumab + Nab-Paclitaxel; Rankl inhibitor. Conditions listed: Triple-negative Breast Cancer; Bone Metastases. Triple-negative eligibility wording from the registry: "Metastatic triple-negative breast cancer (TNBC) confirmed by histological examination, i". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06538896
- Phase: 2
- Setting: Exploratory Single-Arm, Multicenter Phase II Study of Tislelizumab Combined with Nab-Paclitaxel As First Line Treatment for Patients of Triple-negative Breast Cancer(TNBC) with Bone Metastasis
- Sponsor: Zhejiang Cancer Hospital
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06538896: https://clinicaltrials.gov/study/NCT06538896

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06538896.json